¼¼°èÀÇ Àΰ£ »ý½Ä ±â¼ú ½ÃÀå
Human Reproductive Technologies
»óǰÄÚµå : 1513929
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 167 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àΰ£ »ý½Ä ±â¼ú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 346¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»ó

2023³â¿¡ 296¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Àΰ£ »ý½Ä±â¼ú ¼¼°è ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£¿¡¼­ CAGR 2.3%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 346¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÇÀÓ¾à ¹× ÀåÄ¡´Â CAGR 2.6%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 220¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÒÀÓ Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 80¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 3.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Àΰ£ »ý½Ä±â¼ú ½ÃÀåÀº 2023³â 80¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 66¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 3.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.3%¿Í 2.0%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Àΰ£ »ý½Ä ±â¼ú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ ¿ä¾à

Àΰ£ »ý½Ä±â¼ú ½ÃÀåÀº Àα¸µ¿ÅÂÀÇ º¯È­, ±â¼úÀÇ Áøº¸, »çȸ±Ô¹üÀÇ ÁøÈ­°¡ °ãÃÄ Å« ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡´Â ºÒÀÓ·ü »ó½Â°ú °¡Á·°èȹ ÈıâÈ­ÀÇ Ãß¼¼ º¯È­·Î ÀÎÇØ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ºÒÀÓ°ú »ý½Ä¿¡ °üÇÑ °úÁ¦¸¦ ´Ù·ç±â À§ÇÑ ´Ù¾çÇÑ Ä¡·á¿Í ±â¼úÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­, Ãâ»êÀÇ Áö¿¬, »ý½Ä ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¹°ÁúÀÇ ¼Òºñ·® Áõ°¡ µîÀÇ ¿äÀÎÀÌ ºÒÀÓÀÇ ¸¸¿¬À» Á¶ÀåÇϰí, »ý½Ä ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÇÇÐÀÇ Áøº¸·Î ÀÌ·¯ÇÑ ±â¼úÀº º¸´Ù ÀÌ¿ëÇϱ⠽±°í È¿°úÀûÀÎ °ÍÀÌ µÇ¾î, ¼¼°è¿¡¼­ ä¿ëÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷, °æ±¸ ÇÇÀÓ¾àÀº »ç¿ëÇϱ⠽±°í, ³Î¸® ÀÌ¿ë °¡´ÉÇϸç, Åõ¿©µµ °£´ÜÇϱ⠶§¹®¿¡ ÇÇÀÓ¾à ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ¾î, °Ô´Ù°¡, °èȹ¿ÜÀÇ ÀÓ½ÅÀ» ¸·¾Æ, ¼ºÀÇ °Ç°­À» ÃËÁøÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÇÇØ Áö¿øµË´Ï´Ù.

ÀÌ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀ̶ó´Â Á¡¿¡¼­ ü¿Ü¼öÁ¤(IVF)°ú °°Àº »ý½Äº¸Á¶ÀÇ·á±â¼ú(ART)ÀÌ ÇöÀúÇÑ ¹ßÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÁöÀûÀç»ê(IP)À» ART¿¡ ÅëÇÕ, ƯÈ÷ ü¿Ü ¹è¿ìÀÚ Çü¼º(IVG)°ú °°Àº ½Å±â¼úÀº »óȲÀ» Å©°Ô ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ¼¼Æ÷¸¦ ÀçÇÁ·Î±×·¡¹ÖÇÏ¿© Á¤ÀÚ³ª ³­ÀÚ·Î ¼ºÀå½ÃŰ´Â IVG´Â ±âÁ¸¿¡´Â ½ÇÇöÇÒ ¼ö ¾ø¾ú´ø À¯ÀüÀÚÀÇ ¼±ÅÃÀ̳ª º¯°æÀ» °¡´ÉÇÏ°Ô ÇÒ ¼ö ÀÖ¾î, Á¾·¡ÀÇ ¹æ¹ýÀ¸·ÎºÎÅÍÀÇ Å« ÀüȯÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÁöÀû Àç»ê¿¡ ´ëÇÑ Á¢±ÙÀº °øµ¿ÀûÀÌ°í °³¹æÀûÀÎ °øÀ¯ ¸ðµ¨¿¡¼­ º¸´Ù °æÀïÀûÀÎ °ÍÀ¸·Î ÁøÈ­Çϰí ÀÖÀ¸¸ç, ¿¬±¸ÀÚ¿Í ±â¾÷Àº ƯÇãÀÇ È®º¸¸¦ Á¡Á¡ ´õ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ º¯È­´Â IVGÀÇ Å« °æÁ¦Àû ÀáÀç·Â¿¡ ¿µÇâÀ» ¹Þ¾ÒÁö¸¸ »ý½Ä ±â¼ú¿¡¼­ ƯÇãÀÇ ´ë»óÀÌ µÉ ¼öÀÖ´Â ¹°ÁúÀÇ ¹üÀ§¿Í ½ÇÇà °¡´É¼º¿¡ ¿µÇâÀ» ÁÙ ¼öÀÖ´Â º¹ÀâÇÑ À±¸®Àû ¹× ±ÔÁ¦Àû °úÁ¦µµ °¡Á®¿É´Ï´Ù.

Àΰ£ »ý½Ä ±â¼ú ½ÃÀåÀÇ È®´ë´Â ¸î °¡Áö ÁÖ¿ä ÃËÁø¿äÀο¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ³­¼¼Æ÷Áú³» Á¤ÀÚÁÖÀÔ¹ý(ICSI)°ú Âø»óÀü À¯ÀüÀÚÁø´Ü¹ý(PGD) µîÀÇ ±â¼ú Çõ½ÅÀº ºÒÀÓÄ¡·á¿¡ Çõ¸íÀ» °¡Á®¿À°í, ±× È¿´ÉÀ» ³ô¿© ¸Å·ÂÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ART°¡ »çȸÀûÀ¸·Î ¹Þ¾Æµé¿©Áö¸é¼­ ½ºÆ¼±×¸¶(Æí°ß)°¡ °¨¼ÒÇϰí, ƯÈ÷ ¼±ÅÃÀûÀÎ ÇÑ ºÎ¸ð³ª LGBTQ °¡Á· µî ´Ù¾çÇÑ °¡Á· ±¸¼º °£ÀÇ ÀÌ¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ÀÇ·á ´ëÃâ ¼±ÅÃÀÇ È®´ë, »ó¾÷ ÅõÀÚ Áõ°¡, ÁöÁöÀûÀÎ ¹ý °³Á¤¿¡ ÀÇÇØ ÀÌ·¯ÇÑ ±â¼úÀº º¸´Ù ÀÌ¿ëÇϱ⠽¬¿ö º¸±ÞµÇ¾ú½À´Ï´Ù. °Ô´Ù°¡, À¯ÀüÀÚ ½ºÅ©¸®´×ÀÇ Áøº¸¿Í °³ÀÎÈ­µÈ ÀÇ·á µ¿ÇâÀº ´õ¿í ¸ÂÃãÈ­µÇ°í È¿°úÀûÀÎ ºÒÀÓ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ÇÔ²² »ý½Ä±â¼úÀÌ ´Ü¼øÈ÷ ´É·ÂÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó »çȸÀÇ Æ²°ú ±â´ë¿¡ ÅëÇյǰí ÀÖ´Â ¿ªµ¿ÀûÀÎ ½ÃÀåȯ°æÀÌ ¾ç¼ºµÇ¾î ¹Ì·¡ ¼¼´ë°¡ ¾î¶»°Ô Àӽš¤Ãâ»êµÉ °ÍÀΰ¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 12»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Human Reproductive Technologies Market to Reach US$34.6 Billion by 2030

The global market for Human Reproductive Technologies estimated at US$29.6 Billion in the year 2023, is expected to reach US$34.6 Billion by 2030, growing at a CAGR of 2.3% over the analysis period 2023-2030. Contraceptive Drugs & Devices, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$22.0 Billion by the end of the analysis period. Growth in the Infertility Treatment segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.0 Billion While China is Forecast to Grow at 3.9% CAGR

The Human Reproductive Technologies market in the U.S. is estimated at US$8.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 3.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Human Reproductive Technologies Market - Key Trends and Drivers Summarized

The human reproductive technologies market is experiencing substantial growth due to a confluence of demographic shifts, technological advancements, and evolving societal norms. This sector includes a variety of treatments and technologies designed to address fertility and reproduction challenges, with increasing demand driven by higher infertility rates and shifting trends towards later family planning. Factors such as lifestyle changes, delayed childbearing, and higher consumption of substances affecting fertility contribute to the growing prevalence of infertility, prompting greater reliance on reproductive technologies. Medical advancements are making these technologies more accessible and effective, enhancing their adoption across the globe. In particular, the contraceptive segment holds a significant market share due to the ease of use, widespread availability, and simple administration of oral contraceptives, further supported by government initiatives aimed at preventing unplanned pregnancies and promoting sexual health.

In terms of technological innovation within this sector, assistive reproductive technologies (ART) like in vitro fertilization (IVF) have seen notable developments. The integration of intellectual property (IP) into ART, especially with emerging technologies such as in vitro gametogenesis (IVG), is reshaping the landscape. IVG, which involves reprogramming cells to develop into sperm or eggs, represents a significant shift from traditional methods by potentially allowing genetic selection and modification previously unattainable. The approach to IP in this realm has evolved from a collaborative, open-sharing model to a more competitive one, with researchers and companies increasingly seeking to secure patents. This shift is influenced by the substantial financial potential of IVG, although it also brings complex ethical and regulatory challenges that could affect the scope and viability of patentable material in reproductive technologies.

The expansion of the human reproductive technologies market is propelled by several key drivers. Innovations such as intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD) continue to revolutionize fertility treatments, enhancing their effectiveness and broadening their appeal. The growing societal acceptance of ART has reduced stigma and increased usage, particularly among diverse family structures, including single parents by choice and LGBTQ+ families. Additionally, the expansion of healthcare financing options, increased commercial investments, and supportive legislative changes have made these technologies more accessible and popular. Moreover, advancements in genetic screening and the trend toward personalized medicine are enabling more tailored and effective fertility treatments. Collectively, these factors are fostering a dynamic market environment where reproductive technologies are not only advancing in capability but also becoming more integrated into societal frameworks and expectations, significantly impacting how future generations are conceived and born.

Select Competitors (Total 12 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â